Previous close | 2.0000 |
Open | 2.0000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 150.00 |
Expiry date | 2025-01-17 |
Day's range | 2.0000 - 2.0000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
Biogen Inc. (BIIB) closed the most recent trading day at $216.69, moving -0.65% from the previous trading session.
Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.